B1b cells play a key role in producing antibodies (Ab) against T cell-independent type 2 (TI-2) antigens (Ags). However, the factors regulating Ab production by this unique B cell subset are not well understood. In this study, a detailed analysis of the B cell response to TNP-Ficoll was performed using normal mice. TNP-Ficoll delivered i.p. or i.v. induced rapid Ag-specific B-1b cell activation, expansion, isotype switching and plasmablast/plasma cell differentiation. Ag-specific B-1b cell numbers peaked at day 5 and then gradually declined in the spleen but remained elevated in the peritoneal cavity beyond 40 days post-immunization. In addition to expressing CD43, CD44, and CD86, Ag-activated B-1b cells transiently expressed PD-1, which functionally suppressed BCR-induced B-1b cell in vitro proliferation when additional costimulatory signals were lacking. Inhibiting PD-1:PD-1 ligand (PDL) interactions during TNP-Ficoll immunization significantly enhanced Ag-specific B-1b cell expansion and the frequency of IgG isotype switching and plasmablast/plasma cell differentiation. Remarkably, PD-1 mAb blockade during the first week following immunization resulted in significantly increased numbers of both splenic and bone marrow Ag-specific IgG3, but not IgM, secreting cells at both early (day 5) and late (week 6) timepoints. Moreover, Ag-specific serum IgG3, as well as IgG2c, IgG2b, and IgA levels remained significantly elevated in PD-1 mAb-treated relative to control Ab-treated mice for at least 6 weeks post-immunization. Thus, PD-1:PDL interactions occurring shortly after initial TI-2 Ag encounter play a critical role in suppressing Ag-specific B-1b cell expansion and the development of long-term IgG-producing bone marrow and spleen cells.